Muscarinic mechanisms in psychotic disorders

Handbook of Experimental Pharmacology

Volumn 213, Issue , 2012, Pages 233-265

  McKinzie, David L ^a   Bymaster, Frank P ^b  

^a ELI LILLY AND COMPANY   (United States)

^b Euthymics Bioscience Inc   (United States)

Author keywords

Acetylcholine; Allosteric modulators; Antimuscarinic; Cholinergic; CHRM1 5; Knockout mice; M1 M5; Muscarinic receptor agonists; Schizophrenia; Xanomeline

Indexed keywords

2 ETHYL 8 METHYL 2,8 DIAZASPIRO[4.5]DECANE 1,3 DIONE; ALKALOID DERIVATIVE; APOMORPHINE; ARECOLINE; ATROPINE; CEVIMELINE; CHOLINERGIC RECEPTOR; CLOZAPINE; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; HALOPERIDOL; MILAMELINE; MUSCARINE; MUSCARINIC AGENT; MUSCARINIC M1 RECEPTOR; MUSCARINIC M1 RECEPTOR AGONIST; MUSCARINIC M2 RECEPTOR; MUSCARINIC M2 RECEPTOR AGONIST; MUSCARINIC M3 RECEPTOR; MUSCARINIC M4 RECEPTOR; MUSCARINIC M5 RECEPTOR; MUSCARINIC RECEPTOR; NATURAL PRODUCT; OLANZAPINE; OXOTREMORINE; PILOCARPINE; SABCOMELINE; SCOPOLAMINE; UNINDEXED DRUG; XANOMELINE; NEUROLEPTIC AGENT;

ALZHEIMER DISEASE; ANTIDOPAMINERGIC ACTIVITY; ANTIPSYCHOTIC ACTIVITY; ARTICLE; BLURRED VISION; COGNITION; COGNITIVE DEFECT; CONFUSION; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRY SKIN; EXTRAPYRAMIDAL SYMPTOM; FLUSHING; GASTROINTESTINAL TRACT FUNCTION; GENE DELETION; GENETIC ASSOCIATION; HEART RATE; HUMAN; MOLECULAR MECHANICS; NEGATIVE SYNDROME; NONHUMAN; PHENOTYPE; POSITIVE SYNDROME; PREPULSE INHIBITION; PRIORITY JOURNAL; PROTEIN FUNCTION; PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT; TREMOR; VISUAL DISORDER; XEROSTOMIA; ANIMAL; DRUG EFFECT; GENETICS; PHYSIOLOGY; REVIEW;

ANIMALS; ANTIPSYCHOTIC AGENTS; COGNITION; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MUSCARINIC AGONISTS; PSYCHOTIC DISORDERS; RECEPTORS, MUSCARINIC;

EID: 84868306694     PISSN: 01712004     EISSN: 18650325     Source Type: Book Series    
DOI: 10.1007/978-3-642-25758-2_9     Document Type: Article

References (189)

1. Abi-Dargham A, Gil R, Krystal J, Baldwin RM, Seibyl JP, Bowers M, van Dyck CH, Charney DS, Innis RB, Laruelle M (1998) Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. Am J Psychiatry 155:761-767 (Pubitemid 28252654)
2. Achim AM, Maziade M, Raymond E, Olivier D, Merette C, Roy MA (2011) How prevalent are anxiety disorders in schizophrenia? A meta-analysis and critical review on a significant association. Schizophr Bull 37:811-821
3. Anagnostaras SG, Murphy GG, Hamilton SE, Mitchell SL, Rahnama NP, Nathanson NM, Silva AJ (2003) Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant mice. Nat Neurosci 6:51-58 (Pubitemid 36026332)
4. Andersen MB, Fink-Jensen A, Peacock L, Gerlach J, Bymaster F, Lundbaek JA, Werge T (2003) The muscarinic M1/M4 receptor agonist xanomeline exhibits antipsychotic-like activity in Cebus apella monkeys. Neuropsychopharmacology 28:1168-1175
5. Andreasen NC, Carpenter WT Jr (1993) Diagnosis and classification of schizophrenia. Schizophr Bull 19(2):199-214 (Pubitemid 23183145)
6. Araya R, Noguchi T, Yuhki M, Kitamura N, Higuchi M, Saido TC, Seki K, Itohara S, Kawano M, Tanemura K, Takashima A, Yamada K, Kondoh Y, Kanno I, Wess J, Yamada M (2006) Loss of M5 muscarinic acetylcholine receptors leads to cerebrovascular and neuronal abnormalities and cognitive deficits in mice. Neurobiol Dis 24:334-344 (Pubitemid 44572752)
7. Auerbach JM, Segal M (1996) Muscarinic receptors mediating depression and long-term potentiation in rat hippocampus. J Physiol 492:479-493 (Pubitemid 26137757)
8. Barak S (2009) Modeling cholinergic aspects of schizophrenia: focus on the antimuscarinic syndrome. Behav Brain Res 204:335-351
9. Bartko SJ, Romberg C, White B, Wess J, Bussey TJ, Saksida LM (2011) Intact attentional processing but abnormal responding in M1 muscarinic receptor-deficient mice using an automated touchscreen method. Neuropharmacology 61:1366-1378
10. Basile AS, Fedorova I, Zapata A, Liu X, Shippenberg T, Duttaroy A, Yamada M, Wess J (2002) Deletion of the M5 muscarinic acetylcholine receptor attenuates morphine reinforcement and withdrawal but not morphine analgesia. Proc Natl Acad Sci 99:11452-11457 (Pubitemid 34920946)
11. Bennett JP Jr, Enna SJ, Bylund DB, Gillin JC, Wyatt RJ, Snyder SH (1979) Neurotransmitter receptors in frontal cortex of schizophrenics. Arch Gen Psychiatry 36:927-934 (Pubitemid 10121036)
12. Berkeley JL, Gomeza J, Wess J, Hamilton SE, Nathanson NM, Levey AI (2001) M1 muscarinic acetylcholine receptors activate extracellular signal-regulated kinase in CA1 pyramidal neurons in mouse hippocampal slices. Mol Cell Neurosci 18:512-524 (Pubitemid 34008391)
13. Bodick NC, Offen WW, Levey AI, Cutler NR, Gauthier SG, Satlin A, Shannon HE, Tollefson GD, Rasmussen K, Bymaster FP, Hurley DJ, Potter WZ, Paul SM (1997) Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Arch Neurol 54:465-473 (Pubitemid 27172867)
14. Bolam JP, Francis CM, Henderson Z (1991) Cholinergic input to dopaminergic neurons in the substantia nigra: a double immunocytochemical study. Neuroscience 41:483-494
15. Bowie CR, Harvey PD (2006) Cognitive deficits and functional outcome in schizophrenia. Neuropsychiatr Dis Treat 2:531-536 (Pubitemid 46321882)
16. Bradley SR, Lameh J, Ohrmund L, Son T, Bajpai A, Nguyen D, Friberg M, Burstein ES, Spalding TA, Ott TR, Schiffer HH, Tabatabaei A, McFarland K, Davis RE, Bonhaus DW (2010) AC-260584, an orally bioavailable M(1) muscarinic receptor allosteric agonist, improves cognitive performance in an animal model. Neuropharmacology 58:365-373
17. Brady AE, Jones CK, Bridges TM, Kennedy JP, Thompson AD, Heiman JU, Breininger ML, Gentry PR, Yin H, Jadhav SB, Shirey JK, Conn PJ, Lindsley CW (2008) Centrally active allosteric potentiators of the M4 muscarinic acetylcholine receptor reverse amphetamine-induced hyperlocomotor activity in rats. J Pharmacol Exp Ther 327:941-953
18. Breier A, Su TP, Saunders R, Carson RE, Kolachana BS, de Bartolomeis A, Weinberger DR, Weisenfeld N, Malhotra AK, Eckelman WC, Pickar D (1997) Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc Natl Acad Sci U S A 94:2569-2574 (Pubitemid 27136916)
19. Bridges TM, LeBois EP, Hopkins CR, Wood MR, Jones CK, Conn PJ, Lindsley CW (2010a) The antipsychotic potential of muscarinic allosteric modulation. Drug News Perspect 23:229-240
20. Bridges TM, Lewis LM, Weaver CD, Lindsley CW (2010) Discovery of the first mAChR 5 (M5) selective ligand, an M5 positive allosteric modulator (PAM). Probe Reports from the NIH Molecular Libraries Program. National Center for Biotechnology Information. PMID: 21433383
21. Buchanan RW, Conley RR, Dickinson D, Ball MP, Feldman S, Gold JM, McMahon RP (2008) Galantamine for the treatment of cognitive impairments in people with schizophrenia. Am J Psychiatry 165:82-89 (Pubitemid 351704556)
22. Burgard EC, Sarvey JM (1990) Muscarinic receptor activation facilitates the induction of long-term potentiation (LTP) in the rat dentate gyrus. Neurosci Lett 116:34-39 (Pubitemid 20237132)
23. Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC, Seeman P, Wong DT (1996) Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsycho-pharmacology 14:87-96 (Pubitemid 26053226)
24. Bymaster FP, Shannon HE, Rasmussen K, Delapp NW, Mitch CH, Ward JS, Calligaro DO, Ludvigsen TS, Sheardown MJ, Olesen PH, Swedberg MD, Sauerberg P, Fink-Jensen A (1998) Unexpected antipsychotic-like activity with the muscarinic receptor ligand (5R,6R)6-(3-propylthio-1,2,5-thiadiazol-4-yl)-1-azabicyclo[3.2. 1]octane. Eur J Pharmacol 356:109-119
25. Bymaster FP, Nelson DL, DeLapp NW, Falcone JF, Eckols K, Truex LL, Foreman MM, Lucaites VL, Calligaro DO (1999a) Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro. Schizophr Res 37:107-122 (Pubitemid 29167031)
26. Bymaster FP, Shannon HE, Rasmussen K, DeLapp NW, Ward JS, Calligaro DO, Mitch CH, Whitesitt C, Ludvigsen TS, Sheardown M, Swedberg M, Rasmussen T, Olesen PH, Jeppesen L, Sauerberg P, Fink-Jensen A (1999b) Potential role of muscarinic receptors in schizophrenia. Life Sci 64:527-534 (Pubitemid 29066702)
27. Bymaster FP, Felder C, Ahmed S, McKinzie D (2002) Muscarinic receptors as a target for drugs treating schizophrenia. Curr Drug Targets CNS Neurol Disord 1:163-181
28. Bymaster FP, Carter PA, Yamada M, Gomeza J, Wess J, Hamilton SE, Nathanson NM, McKinzie DL, Felder CC (2003a) Role of specific muscarinic receptor subtypes in cholinergic parasym-pathomimetic responses, in vivo phosphoinositide hydrolysis, and pilocarpine-induced seizure activity. Eur J Neurosci 17:1403-1410 (Pubitemid 36560839)
29. Bymaster FP, Felder CC, Tzavara E, Nomikos GG, Calligaro DO, Mckinzie DL (2003b) Muscarinic mechanisms of antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry 27:1125-1143 (Pubitemid 37464958)
30. Calabresi P, Centonze D, Gubellini P, Bernardi G (1999) Activation of M1-like muscarinic receptors is required for the induction of corticostriatal LTP. Neuropharmacology 38:323-326 (Pubitemid 29073555)
31. Cardinal RN, Pennicott DR, Sugathapala CL, Robbins TW, Everitt BJ (2001) Impulsive choice induced in rats by lesions of the nucleus accumbens core. Science 292:2499-2501 (Pubitemid 32601663)
32. Carey GJ, Billard W, Binch H 3rd, Cohen-Williams M, Crosby G, Grzelak M, Guzik H, Kozlowski JA, Lowe DB, Pond AJ, Tedesco RP, Watkins RW, Coffin VL (2001) SCH 57790, a selective muscarinic M(2) receptor antagonist, releases acetylcholine and produces cognitive enhancement in laboratory animals. Eur J Pharmacol 431:189-200 (Pubitemid 33132125)
33. Chan WY, McKinzie DL, Bose S, Mitchell SN, Witkin JM, Thompson RC, Christopoulos A, Lazareno S, Birdsall NJ, Bymaster FP, Felder CC (2008) Allosteric modulation of the muscarinic M4 receptor as an approach to treating schizophrenia. Proc Natl Acad Sci USA 105:10978-10983
34. Cohen LH, Thale T, Tissenbaum MJ (1944) Acetylcholine treatment of schizophrenia. Arch Neurol Psychiatry 51:171-175
35. Conn PJ, Tamminga C, Schoepp DD, Lindsley C (2008) Schizophrenia: moving beyond monoamine antagonists. Mol Interv 8:99-107 (Pubitemid 351549907)
36. Conn PJ, Jones CK, Lindsley CW (2009) Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders. Trends Pharmacol Sci 30:148-155
37. Crook JM, Dean B, Pavey G, Copolov D (1999) The binding of [3 H]AF-DX 384 is reduced in the caudate-putamen of subjects with schizophrenia. Life Sci 64:1761-1771 (Pubitemid 29185535)
38. Crook JM, Tomaskovic-Crook E, Copolov DL, Dean B (2000) Decreased muscarinic receptor binding in subjects with schizophrenia: a study of the human hippocampal formation. Biol Psychiatry 48:381-388
39. Crook JM, Tomaskovic-Crook E, Copolov DL, Dean B (2001) Low muscarinic receptor binding in prefrontal cortex from subjects with schizophrenia: a study of Brodmann's areas 8, 9, 10, and 46 and the effects of neuroleptic drug treatment. Am J Psychiatry 158:918-925 (Pubitemid 32547622)
40. Dalley JW, Mar AC, Economidou D, Robbins TW (2008) Neurobehavioral mechanisms of impulsivity: fronto-striatal systems and functional neurochemistry. Pharmacol Biochem Behav 90:250-260
41. Dasari S, Gulledg AT (2011) M1 and M4 receptors modulate hippocampal pyramidal neurons. J Neurophysiol 105:779-792
42. Davis KL, Kahn RS, Ko G, Davidson M (1991) Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry 148:1474-1486
43. De Klippel N, Sarre S, Ebinger G, Michotte Y (1993) Effect of M1- and M2-muscarinic drugs on striatal dopamine release and metabolism: an in vivo microdialysis study comparing normal and 6-hydroxydopamine-lesioned rats. Brain Res 630:57-64 (Pubitemid 23342826)
44. De Luca V, Wang H, Squassina A, Wong GW, Yeomans J, Kennedy JL (2004) Linkage of M5 muscarinic and alpha7-nicotinic receptor genes on 15q13 to schizophrenia. Neuropsychobiology 50:124-127 (Pubitemid 39077830)
45. Dean B, Crook JM, Opeskin K, Hill C, Keks N, Copolov DL (1996) The density of muscarinic M1 receptors is decreased in the caudate-putamen of subjects with schizophrenia. Mol Psychiatry 1:54-58 (Pubitemid 126442395)
46. Dean B, McLeod M, Keriakous D, McKenzie J, Scarr E (2002) Decreased muscarinic1 receptors in the dorsolateral prefrontal cortex of subjects with schizophrenia. Mol Psychiatry 7:1083-1091 (Pubitemid 36044267)
47. Dean B, Bymaster FP, Scarr E (2003) Muscarinic receptors in schizophrenia. Curr Mol Med 3:419-426. http://www.ncbi.nlm.nih.gov/pubmed/ 7768353 (Pubitemid 36975101)
48. Dean B, Gray L, Keriakous D, Scarr E (2004) A comparison of M1 and M4 muscarinic receptors in the thalamus from control subjects and subjects with schizophrenia. Thalamus Relat Syst 2:287-295 (Pubitemid 38771968)
49. Dencker D, Wortwein G, Weikop P, Jeon J, Thomsen M, Sager TN, Mork A, Woldbye DPD, Wess J, Fink-Jensen A (2011) Involvement of a subpopulation of neuronal M4 muscarinic acetylcholine receptors in the antipsychotic-like effects of the M1/M4 preferring muscarinic receptor agonist xanomeline. J Neurosci 31:5905-5908
50. Deng C, Huang XF (2005) Decreased density of muscarinic receptors in the superior temporal gyrus in schizophrenia. J Neurosci Res 81:883-890 (Pubitemid 41532154)
51. Dernovsek MZ, Sprah L (2009) Comorbid anxiety in patients with psychosis. Psychiatr Danub 21 (suppl 1):43-50
52. Edelstein P, Schultz JR, Hirschowitz J, Kanter DR, Garver DL (1981) Physostigmine and lithium response in the schizophrenias. Am J Psychiatry 138:1078-1081 (Pubitemid 11012809)
53. Eglen RM (1996) Muscarinic M2 and M3 receptor function in smooth muscle. Proc West Pharmacol Soc 39:57-60
54. Felder CC (1995) Muscarinic acetylcholine receptors: Signal transduction through multiple effectors. FASEB J 9:619-625
55. Felder CC, Bymaster FP, Ward J, DeLapp N (2000) Therapeutic opportunities for muscarinic receptors in the central nervous system. J Med Chem 43:4333-4353 (Pubitemid 32046857)
56. Fisher JT, Vincent SG, Gomeza J, Yamada M, Wess J (2004) Loss of vagally mediated bradycardia and bronchoconstriction in mice lacking M2 or M3 muscarinic acetylcholine receptors. FASEB J 18:711-713
57. Friedman JL (2004) Cholinergic targets for cognitive enhancement in schizophrenia: focus on cholinesterase inhibitors and muscarinic agonists. Psychopharmacology (Berl) 174:45-53
58. Gautam D, Heard TS, Cui Y, Miller G, Bloodworth L, Wess J (2004) Cholinergic stimulation of salivary secretion studied with M1 and M3 muscarinic receptor single- and double-knockout mice. Mol Pharmacol 66(2):260-7 (Pubitemid 38989482)
59. Gautam D, Duttaroy A, Cui Y, Han SJ, Deng C, Seeger T, Alzheimer C, Wess J (2006) M1-M3 muscarinic acetylcholine receptor-deficient mice: novel phenotypes. J Mol Neurosci 30:157-160 (Pubitemid 46035357)
60. Gautam D, Jeon J, Li JH, Han SJ, Hamdan FF, Cui Y, Lu H, Deng C, Gavrilova O, Wess J (2008) Metabolic roles of the M3 muscarinic acetylcholine receptor studied with M3 receptor mutant mice: a review. J Recept Signal Transduct Res 28:93-108 (Pubitemid 351588080)
61. Gerber DJ, Sotnikova TD, Gainetdinov RR, Huang SY, Caron MG, Tonegawa S (2001) Hyperactivity, elevated dopaminergic transmission, and response to amphetamine in M1 muscarinic acetylcholine receptor-deficient mice. Proc Natl Acad Sci 98:15312-15317 (Pubitemid 34014011)
62. Gessa GL, Devoto P, Diana M, Flore G, Melis M, Pistis M (2000) Dissociation of haloperidol, clozapine, and olanzapine effects on electrical activity of mesocortical dopamine neurons and dopamine release in the prefrontal cortex. Neuropsychopharmacology 22:642-649 (Pubitemid 30219407)
63. Goff DC, Hill M, Barch D (2011) The treatment of cognitive impairment in schizophrenia. Pharmacol Biochem Behav 99:245-253
64. Gomeza J, Zhang L, Kostenis E, Felder C, Bymaster F, Brodkin J, Shannon H, Xia B, Deng C, Wess J (1999) Enhancement of D1 dopamine receptor-mediated locomotor stimulation in M(4) muscarinic acetylcholine receptor knockout mice. Proc Natl Acad Sci USA 96:10483-10488 (Pubitemid 29422585)
65. Gould E, Woolf NJ, Butcher LL (1989) Cholinergic projections to the substantia nigra from the pedunculopontine and laterodorsal tegmental nuclei. Neuroscience 28:611-623 (Pubitemid 19081019)
66. Gray JA, Roth BL (2007) Molecular targets for treating cognitive dysfunction in schizophrenia. Schizophr Bull 33:1100-1119 (Pubitemid 47347917)
67. Green MF (1996) What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 153:321-330 (Pubitemid 26074706)
68. Gregory KJ, Sexton PM, Christopoulos A (2007) Allosteric Modulation of Muscarinic Acetylcholine Receptors. Curr Neuropharmacol 5:157-167 (Pubitemid 351863857)
69. Grilli M, Patti L, Robino F, Zappettini S, Raiteri M, Marchi M (2008) Release-enhancing presynaptic muscarinic and nicotinic receptors co-exist and interact on dopaminergic nerve endings of rat nucleus accumbens. J Neurochem 105:2205-2213 (Pubitemid 351782252)
70. Gronier B, Rasmussen K (1998) Activation of midbrain presumed dopaminergic neurons by muscarinic cholinergic receptors: an in vivo electrophysiological study in the rat. Br J Pharmacol 124:455-464 (Pubitemid 28254500)
71. Hamilton SE, Nathanson NM (2001) The M1 receptor is required for muscarinic activation of mitogen-activated protein (MAP) kinase in murine cerebral cortical neurons. J Biol Chem 276:15850-15853
72. Heinrich JN, Butera JA, Carrick T, Kramer A, Kowal D, Lock T, Marquis KL, Pausch MH, Popiolek M, Sun SC, Tseng E, Uveges AJ, Mayer SC (2009) Pharmacological comparison of muscarinic ligands: historical versus more recent muscarinic M1-preferring receptor agonists. Eur J Pharmacol 605:53-56
73. Heinrichs RW (2005) The primacy of cognition in schizophrenia. Am Psychol 60:229-242
74. Hill SK, Bishop JR, Palumbo D, Sweeney JA (2010) Effect of second-generation antipsychotics on cognition: current issues and future challenges. Expert Rev Neurother 10:43-57
75. Holtzman RS (1998) The legacy of Atropos, the fate who cut the thread of life. Anesthesiology 89:241-249
76. Hyde TM, Crook JM (2001) Cholinergic systems and schizophrenia: primary pathology or epiphenomena? J Chem Neuroanat 22:53-63 (Pubitemid 32695509)
77. Janowsky DS, El-Yousef MK, Davis JM, Sekerke HJ (1973) Antagonistic effects of physostigmine and methylphenidate in man. Am J Psychiatry 130:1370-1376
78. Jeon J, Dencker D, Wortwein G, Woldbye DP, Cui Y, Davis AA, Levey AI, Schutz G, Sager TN, Mork A, Li C, Deng CX, Fink-Jensen A, Wess J (2010) A subpopulation of neuronal M4 muscarinic acetylcholine receptors plays a critical role in modulating dopamine-dependent behaviors. J Neurosci 30:2396-2405
79. Johnstone EC, Crow TJ, Ferrier IN, Frith CD, Owens DG, Bourne RC, Gamble SJ (1983) Adverse effects of anticholinergic medication on positive schizophrenic symptoms. Psychol Med 13:513-527 (Pubitemid 13019017)
80. Jones CK, Eberle EL, Shaw DB, McKinzie DL, Shannon HE (2005) Pharmacologic interactions between the muscarinic cholinergic and dopaminergic systems in the modulation of prepulse inhibition in rats. J Pharmacol Exp Ther 312:1055-1063 (Pubitemid 40293764)
81. Jones CK, Brady AE, Davis AA, Xiang Z, Bubser M, Tantawy MN, Kane AS, Bridges TM, Kennedy JP, Bradley SR, Peterson TE, Ansari MS, Baldwin RM, Kessler RM, Deutch AY, Lah JJ, Levey AI, Lindsley CW, Conn PJ (2008) Novel selective allosteric activator of the M1 muscarinic acetylcholine receptor regulates amyloid processing and produces antipsychoticlike activity in rats. J Neurosci 28:10422-10433
82. Kalkman HO, Subramanian N, Hoyer D (2001) Extended radioligand binding profile of iloperidone: a broad spectrum dopamine/serotonin/norepinephrine receptor antagonist for the management of psychotic disorders. Neuropsychopharmacology 25:904-914 (Pubitemid 34031895)
83. Kapur S, Mamo D (2003) Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog Neuropsychopharmacol Biol Psychiatry 27:1081-1090 (Pubitemid 37464954)
84. Keefe RS, Malhotra AK, Meltzer HY, Kane JM, Buchanan RW, Murthy A, Sovel M, Li C, Goldman R (2008) Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial. Neuropsychopharmacology 33:1217-1228 (Pubitemid 351521707)
85. Kitazawa T, Hirama R, Masunaga K, Nakamura T, Asakawa K, Cao J, Teraoka H, Unno T, Komori S, Yamada M, Wess J, Taneike T (2008) Muscarinic receptor subtypes involved in carbachol-induced contraction of mouse uterine smooth muscle. Naunyn-Schmiedeberg's Arch Pharmacol 377:503-513
86. Leach K, Loiacono RE, Felder CC, McKinzie DL, Mogg A, Shaw DB, Sexton PM, Christopoulos A (2010) Molecular mechanisms of action and in vivo validation of an M4 muscarinic acetylcholine receptor allosteric modulator with potential antipsychotic properties. Neuropsychopharmacology 35:855-869
87. Lehmann J, Langer SZ (1982) Muscarinic receptors on dopamine terminals in the cat caudate nucleus: neuromodulation of [3H]dopamine release in vitro by endogenous acetylcholine. Brain Res 248:61-69 (Pubitemid 12024459)
88. Levey AI (1993) Immunological localization of m1-m5 muscarinic acetylcholine receptors in peripheral tissues and brain. Life Sci 52:441-448
89. Levey AI, Edmunds SM, Koliatsos V, Wiley RG, Heilman CJ (1995) Expression of m1-m4 muscarinic acetylcholine receptor proteins in rat hippocampus and regulation by cholinergic innervations. J Neurosci 15:4077-4092
90. Li XM, Perry KW, Wong DT, Bymaster FP (1998) Olanzapine increases in vivo dopamine and norepinephrine release in rat prefrontal cortex, nucleus accumbens, and striatum. Psychopharmacology (Berl) 136:153-161 (Pubitemid 28137955)
91. Li Z, Bonhaus DW, Huang M, Prus AJ, Dai J, Meltzer HY (2007) AC260584 (4-[3-(4butylpiperidin-1-yl)-propyl]-7-fluoro-4H-benzo[1,4]oxazin-3-one), a selective muscarinic M1 receptor agonist, increases acetylcholine and dopamine release in rat medial prefrontal cortex and hippocampus. Eur J Pharmacol 572:129-137 (Pubitemid 47429641)
92. Li Z, Snigdha S, Roseman AS, Dai J, Meltzer HY (2008) Effect of muscarinic receptor agonists xanomeline and sabcomeline on acetylcholine and dopamine efflux in the rat brain: comparison with effects of (4-[3-(4-butylpiperidin-1-yl)-propyl]-7-fluoro-4H-benzo[1,4]oxazin-3-one (AC260584) and N-desmethylclozapine. Eur J Pharmacol 596:89-97
93. Liao DL, Hong CJ, Chen HM, Chen YE, Lee SM, Chang CY, Chen H, Tsai SJ (2003) Association of muscarinic m1 receptor genetic polymorphisms with psychiatric symptoms and cognitive function in schizophrenic patients. Neuropsychobiology 48:72-76 (Pubitemid 37176870)
94. Ma L, Seager MA, Wittmann M, Jacobson M, Bickel D, Burno M, Jones K, Graufelds VK, Xu G, Pearson M, McCampbell A, Gaspar R, Shughrue P, Danziger A, Regan C, Flick R, Pascarella D, Garson S, Doran S, Kreatsoulas C, Veng L, Lindsley CW, Shipe W, Kuduk S, Sur C, Kinney G, Seabrook GR, Ray WJ (2009) Selective activation of the M1 muscarinic acetylcholine receptor achieved by allosteric potentiation. Proc Natl Acad Sci USA 106:15950-15955
95. Maehara S, Satow A, Hikichi H, Ohta H (2011a) Antipsychotic effects of N-desmethylclozapine on sensorimotor gating function in rats: possible involvement of activation of M(1) muscarinic receptors. Eur J Pharmacol 667:242-249
96. Maehara S, Okuda S, Ohta H (2011b) Ameliorative effect of N-desmethylclozapine in animal models of social deficits and cognitive functions. Brain Res Bull 86:146-151
97. Mancama D, Arranz MJ, Landau S, Kerwin R (2003) Reduced expression of the muscarinic 1 receptor cortical subtype in schizophrenia. Am J Med Genet B Neuropsychiatr Gene 119B:2-6 (Pubitemid 37064044)
98. Marchi M, Raiteri M (1985) On the presence in the cerebral cortex of muscarinic receptor subtypes which differ in neuronal localization, function and pharmacological properties. J Pharmacol Exp Ther 235:230-233 (Pubitemid 15242387)
99. Marino MJ, Rouse ST, Levey AI, Potter LT, Conn PJ (1998) Activation of the genetically defined m1 muscarinic receptor potentiates N-methyl-D-aspartate (NMDA) receptor currents in hippocampal pyramidal cells. Proc Natl Acad Sci 95:11465-11470 (Pubitemid 28450152)
100. Marlo JE, Niswender CM, Days EL, Bridges TM, Xiang Y, Rodriguez AL, Shirey JK, Brady AE, Nalywajko T, Luo Q, Austin CA, Williams MB, Kim K, Williams R, Orton D, Brown HA, Lindsley CW, Weaver CD, Conn PJ (2009) Discovery and characterization of novel allosteric potentiators of M1 muscarinic receptors reveals multiple modes of activity. Mol Pharmacol 75:577-588
101. McArthur RA, Gray J, Schreiber R (2010) Cognitive effects of muscarinic M1 functional agonists in non-human primates and clinical trials. Curr Opin Investig Drugs 11:740-760
102. McCutchen E, Scheiderer CL, Dobrunz LE, McMahon LL (2006) Coexistence of muscarinic longterm depression with electrically induced long-term potentiation and depression at CA3-CA1 synapses. J Neurophysiol 96:3114-3121 (Pubitemid 44837857)
103. Mendoza MC, Lindenmayer JP (2009) N-desmethylclozapine: is there evidence for its antipsychotic potential? Clin Neuropharmacol 32:154-157
104. Miyakawa T, Yamada M, Duttaroy A, Wess J (2001) Hyperactivity and intact hippocampusdependent learning in mice lacking the M1 muscarinic acetylcholine receptor. J Neurosci 21:5239-5250 (Pubitemid 32622949)
105. Moghaddam B, Bunney BS (1990) Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from the prefrontal cortex, nucleus accumbens, and striatum of the rat: an in vivo microdialysis study. J Neurochem 54:1755-1760
106. Moriya H, Takagi Y, Nakanishi T, Hayashi M, Tani T, Hirotsu I (1999) Affinity profiles of various muscarinic antagonists for cloned human muscarinic acetylcholine receptor (mAChR) subtypes and mAChRs in rat heart and submandibular gland. Life Sci 64:2351-2358 (Pubitemid 29274228)
107. Mrzljak L, Levey AI, Goldman-Rakic PS (1993) Association of m1 and m2 muscarinic receptor proteins with asymmetric synapses in the primate cerebral cortex: morphological evidence for cholinergic modulation of excitatory neurotransmission. Proc Natl Acad Sci USA 90:5194-5198 (Pubitemid 23183004)
108. Murphy BP, Chung YC, Park TW, McGorry PD (2006) Pharmacological treatment of primary negative symptoms in schizophrenia: a systematic review. Schizophr Res 88:5-25 (Pubitemid 44693240)
109. Nathan J, Watson J, Lund J, Peters GL, Dodds CM, Lawrence P, Bentley GD, O'Neill BV, Robertson J, Maruff P, Laruelle M, Bullmore ET (2011) The potent M1 receptor allosteric agonist GSK1034702 improves episodic memory in the nicotine abstinence model of cognitive dysfunction in humans. Am Coll Neuropsychopharmacol 36:S236-S237
110. Neubauer H, Adams M, Redfern P (1975) The role of central cholinergic mechanisms in schizophrenia. Med Hypotheses 1:32-34
111. Newell KA, Zavitsanou K, Jew SK, Huang XF (2007) Alterations of muscarinic and GABA receptor binding in the posterior cingulate cortex in schizophrenia. Prog Neuropsycho-pharmacol Biol Psychiatry 31:225-233 (Pubitemid 44959255)
112. Olianas MC, Maullu C, Onali P (1997) Effects of clozapine on rat striatal muscarinic receptors coupled to inhibition of adenylyl cyclase activity and on the human cloned m4 receptor. Br J Pharmacol 122:401-408 (Pubitemid 27429713)
113. Osterholm RK, Camoriano JK (1982) Transdermal scopolamine psychosis. J Am Med Assoc 247:3081 (Pubitemid 12114458)
114. Perry EK, Perry RH (1995) Acetylcholine and hallucinations: disease-related compared to druginduced alterations in human consciousness. Brain Cogn 28:240-258
115. Perry KW, Nisenbaum LK, George CA, Shannon HE, Felder CC, Bymaster FP (2001) The muscarinic agonist xanomeline increases monoamine release and immediate early gene expression in the rat prefrontal cortex. Biol Psychiatry 49:716-725 (Pubitemid 32328121)
116. Pfeifer CC, Jenny EH (1957) The inhibition of conditioned response and counteraction of schizophrenia by muscarinic stimulation of the brain. Ann N Y Acad Sci 66:753-764
117. Poulin B, Butcher A, McWilliams P, Bourgognon JM, Pawlak R, Kong KC, Bottrill A, Mistry S, Wess J, Rosethorne EM, Charlton SJ, Tobin AB (2010) The M3-muscarinic receptor regulates learning and memory in a receptor phosphorylation/arrestin-dependent manner. Proc Natl Acad Sci USA 107:9440-9445
118. Raedler TJ, Knable MB, Jones DW, Urbina RA, Gorey JG, Lee KS, Egan MF, Coppola R, Weinberger DR (2003) In vivo determination of muscarinic acetylcholine receptor availability in schizophrenia. Am J Psychiatry 160:118-127 (Pubitemid 36042435)
119. Raedler TJ, Bymaster FP, Tandon R, Copolov D, Dean B (2007) Towards a muscarinic hypothesis of schizophrenia. Mol Psychiatry 12:232-246 (Pubitemid 46328501)
120. Ragozzino ME, Mohler EG, Prior M, Palencia CA, Rozman S (2009) Acetylcholine activity in selective striatal regions supports behavioral flexibility. Neurobiol Learn Mem 91:13-22
121. Reichenberg A, Weiser M, Caspi A, Knobler HY, Lubin G, Harvey PD, Rabinowitz J, Davidson M (2006) Premorbid intellectual functioning and risk of schizophrenia and spectrum disorders. Schizophr Res 85:49-57 (Pubitemid 43964990)
122. Reichenberg A, Harvey PD, Bowie CR, Mojtabai R, Rabinowitz J, Heaton RK, Bromet E (2009) Neuropsychological function and dysfunction in schizophrenia and psychotic affective disorders. Schizophr Bull 35:1022-1029
123. Rouse ST, Hamilton SE, Potter LT, Nathanson NM, Conn PJ (2000) Muscarinic-induced modulation of potassium conductances is unchanged in mouse hippocampal pyramidal cells that lack functional M1 receptors. Neurosci Lett 278:61-64 (Pubitemid 30009897)
124. Rowe WB, O'Donnell JP, Pearson D, Rose GM, Meaney MJ, Quirion R (2003) Long-term effects of BIBN-99, a selective muscarinic M2 receptor antagonist, on improving spatial memory performance in aged cognitively impaired rats. Behav Brain Res 145:171-178 (Pubitemid 37188642)
125. Salah-Uddin H, Scarr E, Pavey G, Harris K, Hagan JJ, Dean B, Challiss RA, Watson JM (2009) Altered M(1) muscarinic acetylcholine receptor (CHRM1)-Galpha(q/11) coupling in a schizophrenia endophenotype. Neuropsychopharmacology 34:2156-2166
126. Sanchez G, Alvares Lde O, Oberholzer MV, Genro B, Quillfeldt J, da Costa JC, Cervenansky C, Jerusalinsky D, Kornisiuk E (2009) M4 muscarinic receptors are involved in modulation of neurotransmission at synapses of Schaffer collaterals on CA1 hippocampal neurons in rats. J Neurosci Res 87:691-700
127. Sarter M, Bruno JP (1996) Cognitive functions of cortical acetylcholine: toward a unifying hypothesis. Brain Res Brain Res Rev 23:28-46
128. Sauerberg P, Jeppesen L, Olesen PH, Rasmussen T, Swedberg MD, Sheardown MJ, Fink-Jensen A, Thomsen C, Thøgersen H, Rimvall K, Ward JS, Calligaro DO, DeLapp NW, Bymaster FP, Shannon HE (1998) Muscarinic agonists with antipsychotic-like activity: structure-activity relationships of 1,2,5-thiadiazole analogues with functional dopamine antagonist activity. J Med Chem 41:4378-4384 (Pubitemid 28498761)
129. Scarr E, Keriakous D, Crossland N, Dean B (2006) No change in cortical muscarinic M2, M3 receptors or [35 S]-GTPgammaS binding in schizophrenia. Life Sci 78:1231-1237 (Pubitemid 43176718)
130. Scarr E, Sundram S, Keriakous D, Dean B (2007) Altered hippocampal muscarinic M4, but not M1, receptor expression from subjects with schizophrenia. Biol Psychiatry 61:1161-1170 (Pubitemid 46669465)
131. Scarr E, Cowie TF, Kanellakis S, Sundram S, Pantelis C, Dean B (2009) Decreased cortical muscarinic receptors define a subgroup of subjects with schizophrenia. Mol Psychiatry 14:1017-1023
132. Schmidt LS, Miller AD, Lester DB, Bay-Richter C, Schulein C, Frikke-Schmidt H, Wess J, Blaha CD, Woldbye DP, Fink-Jensen A, Wortwein G (2010) Increased amphetamine-induced locomotor activity, sensitization, and accumbal dopamine release in M5 muscarinic receptor knockout mice. Psychopharmacology (Berl) 207:547-558
133. Schmidt LS, Thomsen M, Weikop P, Dencker D, Wess J, Woldbye DP, Wortwein G, Fink-Jensen A (2011) Increased cocaine self-administration in M4 muscarinic acetylcholine receptor knockout mice. Psychopharmacology (Berl) 216:367-378
134. Seeger T, Fedorova I, Zheng F, Miyakawa T, Koustova E, Gomeza J, Basile AS, Alzheimer C, Wess J (2004) M2 muscarinic acetylcholine receptor knock-out mice show deficits in behavioral flexibility, working memory, and hippocampal plasticity. J Neurosci 24:10117-10127 (Pubitemid 39492037)
135. Shahid M, Walker GB, Zorn SH, Wong EH (2009) Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol 23:65-73
136. Shannon HE, Rasmussen K, Bymaster FP, Hart JC, Peters SC, Swedberg MD, Jeppesen L, Sheardown MJ, Sauerberg P, Fink-Jensen A (2000) Xanomeline, an M(1)/M(4) preferring muscarinic cholinergic receptor agonist, produces antipsychotic-like activity in rats and mice. Schizophr Res 42:249-259 (Pubitemid 30216536)
137. Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu LX, Sibley DR, Roth BL, Mailman R (2003) Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 28:1400-1411 (Pubitemid 41070874)
138. Sheffler DJ, Williams R, Bridges TM, Xiang Z, Kane AS, Byun NE, Jadhav S, Mock MM, Zheng F, Lewis LM, Jones CK, Niswender CM, Weaver CD, Lindsley CW, Conn PJ (2009) A novel selective muscarinic acetylcholine receptor subtype 1 antagonist reduces seizures without impairing hippocampus-dependent learning. Mol Pharmacol 76:356-368
139. Shekhar A, Potter WZ, Lightfoot J, Lienemann J, Dubé S, Mallinckrodt C, Bymaster FP, McKinzie DL, Felder CC (2008) Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. Am J Psychiatry 165:1033-1039
140. Shinoe T, Matsui M, Taketo MM, Manabe T (2005) Modulation of synaptic plasticity by physiological activation of M1 muscarinic acetylcholine receptors in the mouse hippocampus. J Neurosci 25:11194-11200 (Pubitemid 43089564)
141. Shirey JK, Xiang Z, Orton D, Brady AE, Johnson KA, Williams R, Ayala JE, Rodriguez AL, Wess J, Weaver D, Niswender CM, Conn PJ (2008) An allosteric potentiator of M4 mAChR modulates hippocampal synaptic transmission. Nat Chem Biol 4:42-50 (Pubitemid 350273654)
142. Shirey JK, Brady AE, Jones PJ, Davis AA, Bridges TM, Kennedy JP, Jadhav SB, Menon UN, Xiang Z, Watson ML, Christian EP, Doherty JJ, Quirk MC, Snyder DH, Lah JJ, Levey AI, Nicolle MM, Lindsley CW, Conn PJ (2009) A selective allosteric potentiator of the M1 muscarinic acetylcholine receptor increases activity of medial prefrontal cortical neurons and restores impairments in reversal learning. J Neurosci 29:14271-14286
143. Singh MM, Kay SR, Opler LA (1987) Anticholinergic-neuroleptic antagonism in terms of positive and negative symptoms of schizophrenia: implications for psychobiological subtyping. Psychol Med 17:39-48 (Pubitemid 17055152)
144. Spalding TA, Trotter C, Skjaerbaek N, Messier TL, Currier EA, Burstein ES, Li D, Hacksell U, Brann MR (2002) Discovery of an ectopic activation site on the M(1) muscarinic receptor. Mol Pharmacol 61:1297-1302 (Pubitemid 34575739)
145. Stanhope KJ, Mirza NR, Bickerdike MJ, Bright JL, Harrington NR, Hesselink MB, Kennett GA, Lightowler S, Sheardown MJ, Syed R, Upton RL, Wadsworth G, Weiss SM, Wyatt A (2001) J Pharmacol Exp Ther 299:782-792
146. Steidl S, Yeomans JS (2009) M5 muscarinic receptor knockout mice show reduced morphineinduced locomotion but increased locomotion after cholinergic antagonism in the ventral tegmental area. J Pharmacol Exp Ther 328:263-275
147. Stengel PW, Gomeza J, Wess J, Cohen ML (2000) M(2) and M(4) receptor knockout mice: muscarinic receptor function in cardiac and smooth muscle in vitro. J Pharmacol Exp Ther 292:877-885 (Pubitemid 30136578)
148. Stengel PW, Yamada M, Wess J, Cohen ML (2002) M(3)-receptor knockout mice: muscarinic receptor function in atria, stomach fundus, urinary bladder, and trachea. Am J Physiol Regul Integr Comp Physiol 282:R1443-R1449 (Pubitemid 34664532)
149. Stockton ME, Rasmussen K (1996) Electrophysiological effects of olanzapine, a novel atypical antipsychotic, on A9 and A10 dopamine neurons. Neuropsychopharmacology 14:97-105
150. Struckmann N, Schwering S, Wiegand S, Gschnell A, Yamada M, Kummer W, Wess J, Haberberger RV (2003) Role of muscarinic receptor subtypes in the constriction of peripheral airways: studies on receptor-deficient mice. Mol Pharmacol 64:1444-1451 (Pubitemid 37532234)
151. Sur C, Mallorga PJ, Wittmann M, Jacobson MA, Pascarella D, Williams JB, Brandish PE, Pettibone DJ, Scolnick EM, Conn PJ (2003) N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-D-aspartate receptor activity. Proc Natl Acad Sci U S A 100(23):13674-9 (Pubitemid 37444798)
152. Tanahashi Y, Unno T, Matsuyama H, Ishii T, Yamada M, Wess J, Komori S (2009) Multiple muscarinic pathways mediate the suppression of voltage-gated Ca2+ channels in mouse intestinal smooth muscle cells. Br J Pharmacol 158:1874-1883
153. Tandon R, Greden JF (1989) Cholinergic hyperactivity and negative schizophrenic symptoms. A model of cholinergic/dopaminergic interactions in schizophrenia. Arch Gen Psychiatry 46:745-753
154. Tandon R, Shipley JE, Greden JF, Mann NA, Eisner WH, Goodson JA (1991) Muscarinic cholinergic hyperactivity in schizophrenia. Relationship to positive and negative symptoms. Schizophr Res 4:23-30
155. Taylor P, Brown HB (1989) Acetylcholine. In: Siegel GJ et al (eds) Basic neurochemistry: molecular, cellular, and medical aspects, 4th edn. Raven, New York, pp 203-231
156. Thomas RL, Langmead CJ, Wood MD, Challiss RA (2009) Contrasting effects of allosteric and orthosteric agonists on m1 muscarinic acetylcholine receptor internalization and downregulation. J Pharmacol Exp Ther 331:1086-1095
157. Thomas DR, Dada A, Jones GA, Deisz RA, Gigout S, Langmead CJ, Werry TD, Hendry N, Hagan JJ, Davies CH, Watson JM (2010) N-desmethylclozapine (NDMC) is an antagonist at the human native muscarinic M(1) receptor. Neuropharmacology 58:1206-1214
158. Thomsen M, Woldbye DP, Wörtwein G, Fink-Jensen A, Wess J, Caine SB (2005) Reduced cocaine self-administration in muscarinic M5 acetylcholine receptor-deficient mice. J Neurosci 25:8141-8149 (Pubitemid 41292109)
159. Thomsen M, Wortwein G, Fink-Jensen A, Woldbye DP, Wess J, Caine SB (2007) Decreased prepulse inhibition and increased sensitivity to muscarinic, but not dopaminergic drugs in M5 muscarinic acetylcholine receptor knockout mice. Psychopharmacology (Berl) 192:97-110 (Pubitemid 46673887)
160. Thomsen M, Wess J, Fulton BS, Fink-Jensen A, Caine SB (2010) Modulation of prepulse inhibition through both M(1) and M(4) muscarinic receptors in mice. Psychopharmacology (Berl) 208:401-416
161. Tollefson GD, Sanger TM, Lu Y, Thieme ME (1998) Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol. Arch Gen Psychiatry 55:250-258
162. Toru M, Watanabe S, Shibuya H, Nishikawa T, Noda K, Mitsushio H, Ichikawa H, Kurumaji A, Takashima M, Matago N et al (1988) Neurotransmitters, receptors and neuropeptides in postmortem brains of chronic schizophrenic patients. Acta Psychiatr Scand 78:121-137
163. Tzavara ET, Bymaster FP, Felder CC, Wade M, Gomeza J, Wess J, McKinzie DL, Nomikos GG (2003) Dysregulated hippocampal acetylcholine neurotransmission and impaired cognition in M2, M4 and M2/M4 muscarinic receptor knockout mice. Mol Psychiatry 8:673-679 (Pubitemid 36980624)
164. Tzavara ET, Bymaster FP, Davis RJ, Wade MR, Perry KW, Wess J, McKinzie DL, Felder C, Nomikos GG (2004) M4 muscarinic receptors regulate the dynamics of cholinergic and dopaminergic neurotransmission: relevance to the pathophysiology and treatment of related CNS pathologies. FASEB J 18:1410-1412 (Pubitemid 39561597)
165. Veroff AE, Bodick NC, Offen WW, Sramek JJ, Cutler NR (1998) Efficacy of xanomeline in Alzheimer disease: cognitive improvement measured using the Computerized Neuropsychological Test Battery (CNTB). Alzheimer Dis Assoc Disord 12:304-312 (Pubitemid 29050744)
166. Vilaró MT, Palacios JM, Mengod G (1990) Localization of m5 muscarinic receptor mRNA in rat brain examined by in situ hybridization histochemistry. Neurosci Lett 114:154-159 (Pubitemid 20188950)
167. Vilaró MT, Wiederhold KH, Palacios JM, Mengod G (1991) Muscarinic cholinergic receptors in the rat caudate-putamen and olfactory tubercle belong predominantly to the m4 class: in situ hybridization and receptor autoradiography evidence. Neuroscience 40:159-167
168. Volz TJ, Farnsworth SJ, Rowley SD, Hanson GR, Fleckenstein AE (2008) Methylphenidateinduced increases in vesicular dopamine sequestration and dopamine release in the striatum: the role of muscarinic and dopamine D2 receptors. J Pharmacol Exp Ther 327:335-340
169. Wang H, Ng K, Hayes D, Gao X, Forster G, Blaha C, Yeomans J (2004) Decreased amphetamineinduced locomotion and improved latent inhibition in mice mutant for the M5 muscarinic receptor gene found in the human 15q schizophrenia region. Neuropsychopharmacology 29:2126-2139 (Pubitemid 39578903)
170. Watanabe S, Nishikawa T, Takashima M, Toru M (1983) Increased muscarinic cholinergic receptors in prefrontal cortices of medicated schizophrenics. Life Sci 33:2187-2196 (Pubitemid 14234456)
171. Watson J, Brough S, Coldwell MC, Gager T, Ho M, Hunter AJ, Jerman J, Middlemiss DN, Riley GJ, Brown AM (1998) Functional effects of the muscarinic receptor agonist, xanomeline, at 5-HT1 and 5-HT2 receptors. Br J Pharmacol 125:1413-1420 (Pubitemid 28548552)
172. Watt ML, Schober DA, Hitchcock S, Liu B, Chesterfield AK, McKinzie D, Felder CC (2011) Pharmacological characterization of LY593093, an M1 muscarinic acetylcholine receptorselective partial orthosteric agonist. J Pharmacol Exp Ther 338:622-632
173. Weiner DM, Levey AI, Brann MR (1990) Expression of muscarinic acetylcholine and dopamine receptor mRNAs in rat basal ganglia. Proc Natl Acad Sci 87:7050-7054
174. Weiner DM, Meltzer HY, Veinbergs I, Donohue EM, Spalding TA, Smith TT, Mohell N, Harvey SC, Lameh J, Nash N, Vanover KE, Olsson R, Jayathilake K, Lee M, Levey AI, Hacksell U, Burstein ES, Davis RE, Brann MR (2004) The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine. Psychopharmacology (Berl) 177:207-216 (Pubitemid 40109932)
175. Wess J (2012) Novel muscarinic receptor mutant mouse models. Handbook Exp Pharmacol 208:95-117
176. Wess J, Eglen RM, Gautam D (2007) Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development. Nat Rev Drug Discov 6:721-733 (Pubitemid 47342315)
177. Westermeyer J (2006) Comorbid schizophrenia and substance abuse: a review of epidemiology and course. Am J Addict 15:345-355 (Pubitemid 44373580)
178. Woolf NJ (1991) Cholinergic systems in mammalian brain and spinal cord. Prog Neurobiol 37:475-524
179. World Health Organization (2004) The global burden of disease. 2004 update. http://www.who.int/healthinfo/global-burden-disease/GBD-report- 2004update-full.pdf
180. Yamada M, Miyakawa T, Duttaroy A, Yamanaka A, Moriguchi T, Makita R, Ogawa M, Chou CJ, Xia B, Crawley JN, Felder CC, Deng CX, Wess J (2001) Mice lacking the M3 muscarinic acetylcholine receptor are hypophagic and lean. Nature 410:207-212 (Pubitemid 32216592)
181. Yamada M, Basile AS, Fedorova I, Zhang W, Duttaroy A, Cui Y, Lamping KG, Faraci FM, Deng CX, Wess J (2003) Novel insights into M5 muscarinic acetylcholine receptor function by the use of gene targeting technology. Life Sci 74:345-353 (Pubitemid 37357065)
182. Yamasaki M, Matsui M, Watanabe M (2010) Preferential localization of muscarinic M1 receptor on dendritic shaft and spine of cortical pyramidal cells and its anatomical evidence for volume transmission. J Neurosci 30:4408-4418
183. Yasuda RP, Ciesla W, Flores LR, Wall SJ, Li M, Satkus SA, Weisstein JS, Spagnola BV, Wolfe BB (1993) Development of antisera selective for m4 and m5 muscarinic cholinergic receptors: distribution of m4 and m5 receptors in rat brain. Mol Pharmacol 43:149-157 (Pubitemid 23055057)
184. Yeomans JS (1995) Role of tegmental cholinergic neurons in dopaminergic activation, antimuscarinic psychosis and schizophrenia. Neuropsychopharmacology 12:3-16
185. Zavitsanou K, Katsifis A, Mattner F, Huang XF (2004) Investigation of m1/m4 muscarinic receptors in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression disorder. Neuropsychopharmacology 29:619-625
186. Zavitsanou K, Katsifis A, Huang XF (2005) M2/M4 muscarinic receptor binding in the anterior cingulate cortex in schizophrenia and mood disorders. Brain Res Bull 65:397-403
187. Zeng XP, Le F, Richelson E (1997) Muscarinic m4 receptor activation by some atypical antipsychotic drugs. Eur J Pharmacol 321:349-354 (Pubitemid 27105938)
188. Zhang W, Yamada M, Gomeza J, Basile AS, Wess J (2002) Multiple muscarinic acetylcholine receptor subtypes modulate striatal dopamine release, as studied with M1-M5 muscarinic receptor knock-out mice. J Neurosci 22:6347-6352 (Pubitemid 35386389)
189. Zorn SH, Jones SB, Ward KM, Liston DR (1994) Clozapine is a potent and selective muscarinic M4 receptor agonist. Eur J Pharmacol 269:R1-R2 (Pubitemid 24348040)